Dr. Lyle Bootman discusses how life sciences companies can bring value to ACOs.
Dr. Mark Callahan explores the most effective strategy for contracting with ACOs.
Dr. David Harlow describes an effective ACO/industry partnership.
Dr. Mark Sorrentino highlights what life sciences companies should focus on as they plan for the future.
ACOs & Industry
The Collaboration Continues
Accountable care organizations (ACOs) present an opportunity for pharmaceutical, biotech, and device companies to position themselves as partners in driving better service and higher quality care—at reduced costs. And companies that find common ground with ACOs will have a competitive advantage as these models continue to evolve.
But what do ACOs want from the industry?
At the 2014 ACOs and Industry: The Collaboration Continues conference, ACO executives and attendees discussed key business questions related to healthcare reform and its impact on the industry including:
• How are ACOs working with the industry to better manage population health?arketing organizations position their products with ACOs?
• What kind of outcomes data do ACOs want from the industry?
• What challenges do ACOs face as they move forward, and what opportunities are available for collaborating on solutions?
• Which resources should companies provide to deliver the most value to ACOs?
• How might health insurance exchanges impact the evolution • How might health insurance exchanges impact the evolution of ACOs?